NEKTAR THERAPEUTICS
NKTR · XNASCIK 906709fmd_1PRKKERQYCJK3GB8M9A3TTAA68Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 165 | 308 | 1,193 | 115 | 153 | 102 | 92 | 90 | 98 | 55 |
| Cost of revenue | 30 | 31 | 24 | 21 | 19 | 25 | 22 | 34 | 31 | 0 |
| Gross profit | 135 | 277 | 1,169 | 93 | 133 | 77 | 70 | 56 | 68 | 55 |
| Research and development | 204 | 268 | 400 | 435 | 409 | 400 | 218 | 114 | 121 | 117 |
| Operating income | (113) | (60) | 688 | (440) | (425) | (446) | (376) | (264) | (105) | (140) |
| Interest expense | 22 | 22 | 22 | 21 | 7 | 0 | 0 | – | – | – |
| Interest and investment income | – | – | – | – | – | 3 | 7 | 19 | 15 | 10 |
| Other non-operating income (expense) | (40) | (36) | (5) | (0) | (19) | (77) | 11 | (13) | (14) | (15) |
| Income before taxes | (153) | (96) | 683 | (440) | (444) | (523) | (365) | (276) | (119) | (164) |
| Income tax expense | 1 | 1 | 1 | 1 | 0 | 1 | 3 | (0) | (0) | (0) |
| Net income from continuing operations | (154) | (97) | 681 | (441) | (444) | (524) | (368) | (276) | (119) | (164) |
| Net income | (154) | (97) | 681 | (441) | (444) | (524) | (368) | (276) | (119) | (164) |